Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions. The new compound has unique chemical properties that allow for precise activation and can be used for tracking its activity in vivo thanks to the emission of fluorescence.
Research was published online in the Journal of Medicinal Chemistry.
The ER is a cellular structure that oversees protein folding and assembly, and it activates stress response mechanisms in response to the accumulation of misfolded proteins or other stressful conditions, including low oxygen.
“Certain cancers rely on the protective role of the ER stress response to sustain their growth in stressful environmental conditions,” said Chih-Chi Andrew Hu, Ph.D., associate professor in Wistar’s Immunology, Microenvironment & Metastasis Program, and co-lead author on the study with Juan R. Del Valle, Ph.D., from the University of South Florida. “We and other groups showed that genetically and pharmacologically targeting the ER is a very effective way to attack various tumors.”
The Hu lab has been actively advancing a research program for development of compounds to block vital functions of the ER stress response, specifically inhibitors of the IRE1 protein that senses the ER stress and responds by activating a cascade of cellular events. In addition to inducing tumor cell apoptosis, these compounds activate antitumor T-cell function and inhibit tumor-associated immunosuppressive cells in vivo in mouse models, resulting in tumor shrinkage.
“This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma,” said Hu. “Therefore, we are very interested in advancing them to the clinic.”
In this study, through a series of chemical modifications, Hu and collaborators created a molecule called PC-D-F07 that is pharmacologically inactive and requires UV irradiation to be “turned on” and converted into the active D-F07, which is a very potent inhibitor of IRE-1 function.
The novel prodrug strategy enhances the efficacy of IRE-1 inhibitors and allows fine control of their activity at a precise time and location by UV irradiation. Importantly, once active, D-F07 emits fluorescence that can be tracked in cells and potentially in vivo, providing a real-time therapy readout. This new strategy for stimulus-mediated release of pharmacological activity provides a promising platform to target the ER stress response for anticancer therapy and for developing other potent inhibitors.
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Dr. Roach: Surgery is standard treatment for penile canceron October 7, 2020 at 8:11 pm
What can you tell me about cancer of the penis? I can’t seem to find information. —S.S. Dear S.S.: Cancer of the penis is quite rare in industrialized nations, accounting for less than 1% of all ...
- 'Continue Cancer Care With Caution' Despite Pandemicon October 7, 2020 at 11:50 am
New data show morbidity and mortality rates from COVID-19 are similar for individuals with or without cancer, suggesting that cancer care can be continued despite the pandemic.
- Trans woman urges to be 'proactive' after rare breast cancer diagnosison October 7, 2020 at 6:23 am
When she learned she had cancer, Beverly Lipscomb worried how the doctors would treat her because she is transgender.
- Does Cancer Chemotherapy Increase My Covid Risks?on October 7, 2020 at 5:49 am
People with cancer, especially leukemia, are at higher risk of dying from Covid-19, though chemotherapy does not appear to increase the risk.
- CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Canceron October 7, 2020 at 5:04 am
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today ...
- GenesisCare Acquires Ten New ExacTrac Dynamic Systems for Advanced Cancer Treatment Following FDA Clearanceon October 7, 2020 at 4:06 am
Brainlab to deliver 10 systems to GenesisCare in the US bringing total investment by the international oncology provider to over 30 systems globally.
- 'Tread Lightly' on De-escalation of Breast Cancer Therapyon October 6, 2020 at 9:03 am
Practice-changing data suggest de-escalation of treatment in breast cancer, but are they relevant to minority patients who are 'grossly underrepresented' in clinical trials?
- Stevenage widow 'angry' after Covid delays cancer treatmenton October 6, 2020 at 7:30 am
A widow says she feels "angry and disgusted" about the death of her husband after his cancer treatment was delayed by three months due to Covid. Mal Watkins, 73, died in September at the Lister ...
- What coverage does Medicare provide for bladder cancer?on October 6, 2020 at 4:54 am
Medicare covers treatment and services relating to bladder cancer. Some out-of-pocket costs may apply. Read on for more information.
- Ron Rivera plans to keep coaching Washington, even amid difficulties from cancer treatmenton October 5, 2020 at 4:25 pm
After a rough week of cancer treatment, Ron Rivera said he plans to keep coaching the Washington Football Team.
via Bing News